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Hippo kinases in breast cancer 
Research paper 
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Abstract 
The Hippo kinases MST1/2 and LATS1/2 inhibit the oncoproteins TAZ/YAP and regulate T cell function. 
Hippo kinases also cooperate with the ATR-Chk1 and ATM-Chk2 pathways, central orchestrators of the 
DNA damage response (DDR). We hypothesized that MST1/2 and LATS1/2 localization differently impacts 
the efficacy of neoadjuvant therapy (NAT) in breast cancer, being protective when expressed in the cytoplasm 
of tumor cells and in tumor-infiltrating lymphocytes, whereas representing molecular determinants of 
chemoresistance when present in the nucleus as a consequence of their cooperation with the DDR. Diagnostic 
biopsies from 57 HER2-positive and triple-negative breast cancer patients treated with NAT were 
immunostained for evaluating the expression of phosphorylated MST1/2 (pMST1/2) and LATS1/2 
(pLATS1/2) in tumor-infiltrating lymphocytes (TILs) and in cancer cells. TAZ and Chk1 immunostaining 
was exploited for investigating subcellular compartment-dependent activity of Hippo kinases. Nuclear 
pMST1/2 (pMST1/2
nuc
) expression was significantly associated with nuclear expression of Chk1 (p = 0.046), 
whereas cytoplasmic pMST1/2 (pMST1/2
cyt
) expression was marginally associated with cytoplasmic TAZ 
staining (p = 0.053). Patients whose tumors expressed pMST1/2
nuc
 were at increased risk of residual disease 
after NAT (pCR ypT0/is ypN0: OR 4.91, 95%CI: 1.57-15.30; pCR ypT0 ypN0: OR 3.59, 95%CI 1.14-11.34). 
Conversely, exclusive cytoplasmic localization of pMST1/2 (pMST1/2
cyt
)seemed to be a protective factor 
(pCR ypT0/is ypN0: OR 0.34, 95%CI: 0.11-1.00; pCR ypT0 ypN0: OR 0.31, 95%CI 0.10-0.93). The 
subcellular localization-dependent significance of pMST1/2 expression suggests their involvement in 
different molecular networks with opposite impact on NAT efficacy. Larger studies are warranted to confirm 
these novel findings. 
Keywords 
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Introduction 
The evolutionary conserved Hippo pathway is a central regulator of tissue growth and cell fate.
1
 In recent 
years, a wave of studies in animal models has demonstrated that its perturbation triggers tumorigenesis.
2
 The 
core of the pathway (regulatory module) comprises the serine/threonine kinases mammalian STE20-like 
protein kinase 1 and 2 (MST1/2) and large tumor suppressor homolog 1 and 2 (LATS1). Hippo kinases, 
together with the adaptor proteins Salvador homologue 1 (SAV1) and MOB kinase activator 1A and 1B 
(MOB1A and MOB1B), mediate an inhibitory phosphorylation of two homologous oncoproteins: the 
transcriptional co-activator with PDZ-binding motif (TAZ) and Yes-associated protein (YAP).
1,2
 When 
TAZ/YAP are phosphorylated by Hippo kinases, they are retained in the cytoplasm, excluded from the 
nucleus, and undergo β-TRCP (β-transducin repeat-containing E3 ubiquitin protein ligase)-dependent 
degradation by the proteasome machinery.
1,2
 Thus, it is generally accepted that the regulatory module exerts 
tumor-suppressive activities by negatively regulating the oncogenic Hippo transducers TAZ/YAP. 
Overwhelming preclinical evidence linked Hippo pathway deregulation to breast cancer (BC).
3,4
 Among the 
plethora of tumor-promoting functions elicited by alterations in the Hippo signaling, particularly remarkable 
are those at the breast cancer stem cell (BCSC) level.
5-9
 Indeed, studies investigating the biological 
consequences of aberrant Hippo activity in BCSCs configured a scenario where activation of TAZ/YAP-
driven gene transcription promotes self-renewal, epithelial-mesenchymal transition (EMT), therapeutic 
resistance and distant dissemination.
5-9
 Consistently, proof-of-concept, retrospective studies carried out by our 
group suggested that the expression of TAZ/YAP is associated with adverse therapeutic and survival 
outcomes in BC patients.
10-12
 Nevertheless, the connection between the Hippo cascade and cancer extends 
beyond the canonical functions of the pathway. For instance, Hippo is involved in the biology of non-
malignant cells residing in the tumor microenvironment. In the context of the immune system, a non-
canonical, Hippo/MST pathway is emerging as a central orchestrator of T cells activities, being implicated in 
an array of functions spanning from T cells development and activation to survival and trafficking.
13
 Another 
level of regulation of core Hippo kinases refers to their cooperation with central nodes of the DNA damage 
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response (DDR) machinery, chiefly the ataxia telangiectasia and Rad3-related protein (ATR)-Checkpoint 
kinase 1 (Chk1) and ataxia telangiectasia mutated (ATM)-Checkpoint Kinase 2 (Chk2) signaling avenues.
14
 
The ATR-chk1 and ATM-Chk2 pathways are deputed to initiate DNA repair upon genotoxic injuries, and 
their over-activation confers chemoresistant features.
15
 Mechanistic studies unveiled that the Hippo-DDR 
cooperation promotes replication fork stability, cell-cycle checkpoint activation and DNA repair.
14 
On this premise, we hypothesized that the expression of phosphorylated MST1/2 (pMST1/2) and LATS1/2 
(pLATS1/2) may be associated with the efficacy of neoadjuvant therapy (NAT) in BC patients in a context-
dependent manner. In greater detail, we envisioned the following “Janus-faced” role for Hippo kinases: i) 
protective when expressed in tumor-infiltrating lymphocytes (TILs), as involved in T cells activation, ii) 
protective when expressed in the cytoplasm of cancer cells, where they supposedly act in the canonical Hippo 
signaling inhibiting oncogenic TAZ/YAP, and iii) detrimental when localized in the nucleus of cancer cells, 
as a consequence of their interactions with central components of the DDR cascade that, in turn, fuel 
chemoresistance. To test this hypothesis, the expression of pMST1/2 and pLATS1/2 was evaluated by 
immunohistochemistry in diagnostic biopsies from 57 HER2-positive and triple-negative breast cancer 
(TNBC) patients treated with NAT. A subset of samples was immunostained for TAZ and Chk1,
10,16
 enabling 
us to investigate whether subcellular localization of Hippo kinases is consistent with their participation in 
different molecular circuits, namely the Hippo signaling cascade for cytoplasmic localization and the DDR 
for nuclear localization. The choice of the aforementioned BC molecular subtypes is rooted into i) the 
emerging relationship between deregulation of the Hippo machinery and the most aggressive BC 
subtypes,
3,6,17
 ii) a wider use of NAT in HER2-positive and TNBC patients compared with patients diagnosed 
with HER2-negative/hormone receptor positive diseases, and iii) our previous studies providing initial hints 
on the predictive significance of Hippo biomarkers in the HER2-positive and TNBC backgrounds.
10,11
 
Materials and Methods 
Patients 
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For this retrospective study, 57 patients with histologically confirmed HER2-positive or triple-negative BC 
were included. Patients were considered eligible if they completed the planned treatment, data on clinical-
pathological features including stage, estrogen receptor (ER) status, progesterone receptor (PgR) status, Ki-
67, HER2, tumor grade, and pCR were available, and if both pMST1/2 and pLATS1/2 were evaluable in the 
cellular compartments of interest (tumor cells and TILs). NAT consisted in anthracycline-taxane-based 
chemotherapy, together with trastuzumab for patients with HER2-postive tumors, as detailed 
elsewhere.
10,11,16
. The impact of pMST1/2 and pLATS1/2 on pCR was evaluated considering the two most 
common definitions of pCR: i) no invasive or noninvasive residual cancer in breast or nodes (ypT0 ypN0), 
according to the definition prevalently adopted by the German Breast Group, and ii) no residual invasive 
tumor in both breast and axilla irrespective of the presence of ductal carcinoma in situ (ypT0/is ypN0). This 
study has been conducted in accordance to the Declaration of Helsinki and approved by the Ethics Committee 
of the “Regina Elena” National Cancer Institute of Rome, the coordinating centre (CEC/532/15, 09-06-2015). 
Written informed consents were obtained before chemotherapy. 
Immunohistochemistry 
The immunohistochemical assessment of pMST1/2 and pLATS1/2 was performed in formalin-fixed paraffin-
embedded (FFPE) tissues, related to diagnostic biopsies, using the following antibodies: anti-MST1/2 
(phospho T183) rabbit polyclonal antibody (Abcam) at the dilution of 1:50 (pH 8); and anti-LATS1/2 
(phospho T1079 and T1041) rabbit polyclonal antibody (Abcam) at the dilution of 1:100 (pH 6). In cancer 
cells, pMST1/2 and pLATS1/2 staining intensity was considered as negative (0), weak (1+), moderate (2+) or 
strong (3+). The variables pMST1/2
cyt
 and pLATS1/2
cyt 
were generated consideringa distinct cytoplasmic 
immunoreactivity of any intensity in at least 10% of tumor cells, in the absence of nuclear staining. The 
variables pMST1/2
nuc
 and pLATS1/2
nuc
 were obtained consideringa distinct nuclear immunoreactivity of any 
intensity in at least 10% of tumor cells, independently from the presence of concomitant cytoplasmic staining. 
Stromal TILs were considered as positive when representing ≥50% of the stromal surface area.18 pMST1/2 
and pLATS1/2 expression in TILs was considered positive when they were expressed in at least 10% of 
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stromal TILs. Immunoreactions were scored independently by two investigators (CE and ADB) blinded to 
treatment outcomes and discordant cases were reviewed for the final assessment. 
Statistical analysis 
Characteristics of the study participants were summarized by descriptive statistics. The relationships between 
pMST1/2 and pLATS1/2, clinical-molecular features and pCR were assessed with the Pearson’s Chi-squared 
(Chi2) test of independence (2-tailed), the Fisher Exact test (F) when required on the basis of the size of the 
groups compared, or the Mann-Whitney test depending on the nature of the variables considered. The 
relationship between continuous variables was assessed with the Pearson correlation coefficient (r
2
). Clinical 
and molecular factors potentially impacting the outcome of interest (pCR) were tested in univariate logistic 
regression models whose estimates were reported as Odds Ratio (OR) and 95% Confident Interval (CI). p 
values inferior to 0.05 were considered as statistically significant. Statistical analyses were performed with 
SPSS software (SPSS version 21, SPSS Inc., Chicago, IL, USA). 
Results 
Baseline clinical-pathological characteristics of participants are summarized in Table 1. Twenty-eight (49%) 
and 23 (40%) patients achieved a pCR according to the definition ypT0/is ypN0 and ypT0 ypN0, respectively. 
Immunohistochemical staining of two representative cases is illustrated in Figure 1. Expression of pMST1/2 
and pLATS1/2 in TILs was recorded in 14 (25%) and 24 (42%) tumor samples, respectively (Table 2). 
pMST1/2 was expressed in the nucleus (pMST1/2
nuc
) in 25 (44%) tumors, and 25 (44%) cases displayed an 
exclusive cytoplasmic localization (pMST1/2
cyt
) (Table 2). A lower number of tumors had exclusive 
pLATS1/2 cytoplasmic expression (pLATS1/2
cyt
), whereas nuclear expression of pLATS1/2 (pLATS1/2
nuc
) 
was recorded in 45 (78%) cases (Table 2). 
Significant or borderline significant associations between the investigated molecular markers and standard 
clinical-pathological features are presented in Table 3. pMST1/2
nuc 
expression was significantly more 
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frequent in TNBC (Chi2 p = 0.001); conversely, pMST1/2
cyt 
expression was significantly more frequent in the 
HER2-positive background (Chi2 p = 0.010). Moreover, a significant positive correlation was seen between 
the percentage of pMST1/2-expressing stromal TILs and the percentage of stromal TILs (r
2 
= 0.395; p = 
0.002; data available upon request). 
As illustrated in Figure 2 (panel A), a borderline significant association was observed between pMST1/2
cyt
 
and cytoplasmic TAZ expression (Chi2 p = 0.053; N = 42). Moreover, a significant association was observed 
between pMST1/2
nuc 
and nuclear expression of phosphorylated Chk1 (pChk1) (F p = 0.046; N = 22) (Figure 
2, panel B). These data suggest that subcellular localization of pMST1/2is consistent with their involvement 
in the canonical Hippo cascade and the DDR network when present in the cytoplasm and in the nucleus, 
respectively. 
We next investigated the predictive significance of pMST1/2 and pLATS1/2 expression. We did not record 
any significant relationship between pLATS1/2 and pCR, irrespective of whether we considered their 
expression in the cytoplasm or in the nucleus (data available upon request). Likewise, neither pLATS1/2 nor 
pMST1/2 expression in stromal TILs predicted pCR (data available upon request). Conversely, a significant 
lower rate of pCR (ypT0/is ypN0) was observed for tumors expressing pMST1/2
nuc
 (Chi2 p = 0.005), and this 
association was maintained even when considering pCR as ypT0 ypN0 (Chi2 p = 0.026) (Table 4). 
Interestingly, an opposite pattern emerged when we addressed the predictive ability of pMST1/2
cyt
, as the 
pCR rate was significantly higher in patients whose tumors carried pMST1/2
cyt 
(Chi2 p = 0.047 and p = 0.033 
for ypT0/is ypN0 and ypT0 ypN0, respectively) (Table 4). Univariate analyses, presented in Figure 3, 
indicated that patients with pMST1/2
nuc
-expressing tumors were at increased risk of residual cancer after 
NAT (OR 4.91, 95%CI: 1.57-15.30 for pCR evaluated as ypT0/is ypN0; OR 3.59, 95%CI 1.14-11.34 for pCR 
evaluated as ypT0 ypN0), whereas those expressing pMST1/2
cyt
 had an opposite outcome (OR 0.34, 95%CI: 
0.11-1.00 for pCR evaluated as ypT0/is ypN0; OR 0.31, 95%CI 0.10-0.93 for pCR evaluated as ypT0 ypN0). 
Discussion 
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In the present study, we investigated the expression of activated core Hippo pathway kinases (pMST1/2 and 
pLATS1/2) in a series of 57 HER2-positve and triple-negative BC patients who received NAT. The message 
conveyed by the present study is that: i) the co-expression pattern observed between pMST1/2
nuc 
and nuclear 
pChk1 expression, and between pMST1/2
cyt
 and cytoplasmic TAZ expression, support the hypothesis that 
MST1/2 participate in different molecular networks, ii) the reduced pCR rate observed in patients with 
pMST1/2
nuc
-expressing tumors plausibly reflects their connection with the DDR, and the related increased 
ability of cancer cells to protect their genome when challenged with chemotherapy, and iii) the increased pCR 
rate recorded in patients with exclusive pMST1/2 cytoplasmic expression is consistent with their function in 
the canonical Hippo cascade, resulting in the inhibition of nuclear accumulation of tumor-promoting Hippo 
transducers. The logic behind the assessment of Hippo kinases in TILs also deserves to be mentioned. First, a 
link is emerging between stromal TILs and pCR in the HER2-positive and triple-negative backgrounds.
19,20
 
Second, our earlier data pointed to the activation of the immune-related Hippo/MST pathway as a potential 
protective factor in cervical cancer patients treated with NAT.
21
 Thus, we also strove to investigate whether 
molecular characterization of TILs improve the predictive significance of current methods of stromal TILs 
assessment. Even though we did not appreciate any significant impact of Hippo kinases on pCR when 
expressed in stromal TILs, the positive correlation recorded between stromal TILs and pMST1/2 expression 
might suggest activation of the non-canonical, immune-related Hippo/MST pathway. On this basis, molecular 
characterization of TILs, relying on a more extensive Hippo pathway analysis, is advised to add granularity to 
current criteria of TILs evaluation, as well as to provide further insight into the molecular signals that either 
boost or depress the anticancer immune response. It is worth mentioning that various types of immune cells 
cohabit the tumor microenvironment (e.g. T cells, macrophages and myeloid-derived suppressor cells), and 
that the presence of different immune cells may have different impact on clinical outcomes.
22
 Even though 
the nature of the immune infiltrate was not specifically assessed in the present study, a more thorough 
characterization of immune cells was planned in our ongoing studies, focusing on pathways potentially 
regulating the antitumor immunity. 
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We acknowledge that this study, when considering its retrospective design and the size of the cohort 
examined, needs to be considered as proof-of-concept. Nevertheless, the subcellular localization-dependent 
association between pMST1/2 and pCR, together with the different distribution of Hippo kinases, more 
frequently expressed in the nucleus in TNBC and in the cytoplasm in the HER2-positive setting, suggest that 
Hippo kinases may be endowed of subtype-specific functions. Recollecting this evidence, we envisioned that, 
while Hippo kinases may be intertwined with cell cycle checkpoints and DNA damage repair effectors in 
TNBC, they prevalently operate in the context of the canonical Hippo machinery in HER2-driven BC. This is 
consistent with preclinical studies describing that key Hippo pathway components are targeted by the 
ATM/Chk2 and ATR/Chk1 pathways,
23-26
 as well as with our previous findings describing a lower pCR rate 
in TNBC patients with elevated expression levels of DDR-linked biomarkers in their tumors.
16
 Next, evidence 
that both estrogens, via G protein-coupled estrogen receptor (GPER), and HER2 via mechanotransduction, 
intersect the Hippo pathway corroborates the hypothesis of molecular subtype-dependent levels of Hippo 
pathway regulation in BC.
27,28
 
The data herein presented provide hints which may help shape a molecular scenario where Hippo kinases 
exert distinct functions in relation to the underlying molecular background (subtype) of BC. However, the 
limitations potentially arising from the use of one single investigational approach, i.e., immunostaining, along 
with the hypothesis generating nature of the evidence provided, prompted the design of ad hoc studies in 
adequately sized cohorts to investigate the topic of interest to a deeper extent, with special emphasis being 
placed on TNBC given the well-established defects in the DDR machinery carried by this disease. To this 
end, an extensive pathway-level analysis will be carried out, envisioning the evaluation of a number of 
molecular processes related to the DDR and genomic stability that include, beyond central Hippo and DDR 
kinases, the assessment of biomarkers related to oncogene-induced replication stress and mitotic 
catastrophe.
29,30
 In doing so, immunohistochemical data will be integrated by the evidence from dedicated 
platforms for genomic and transcriptomic analyses. We will rely on samples collected in the context of a 
prospective, observational trial where neoadjuvant chemotherapy consists in a modified carboplatin-
 11 
 
containing regimen, thus enabling us to gather information from patients treated with a more effective 
regimen than anthracycline- and taxane-containing chemotherapy.
31,32
 
Overall, our data point to the Hippo kinases MST1/2 as potential predictive biomarkers in HER2-positive and 
triple-negative BC patients candidate to receive NAT. The complexity of molecular stimuli that tune Hippo 
pathway effectors and the different circuits where they operate deserves further consideration in future 
studies, and requires the assessment of a wider number of biomarkers for mapping specific molecular 
networks and functions. 
Disclosure of interest 
The authors report no conflict of interest. 
Acknowledgments 
We thank Tania Merlino and Ana Maria Edlisca for editorial assistance. 
Funding details 
This study was supported by an intramural research grant to PV and MM-S. 
  
 12 
 
References 
1. Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and 
cancer treatment. Nat Rev Drug Discov. 2014;13:63-79.  
2. Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev. 
2014;94:1287-312.   
3. Maugeri-Saccà M, Barba M, Pizzuti L, Vici P, Di Lauro L, Dattilo R, Vitale I, Bartucci M, Mottolese M, 
De Maria R. The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical 
implications. Expert Rev Mol Med. 2015;17:e14. 
4. Maugeri-Saccà M, De Maria R. Hippo pathway and breast cancer stem cells. Crit Rev Oncol Hematol. 
2016;99:115-22.  
5. Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi 
G, Sperati F, et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. 
Oncogene. 2015;34:681-90. 
6. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti 
AR, Poletti A, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. 
Cell. 2011;147:759-72. 
7. Xiang L, Gilkes DM, Hu H, Takano N, Luo W, Lu H, Bullen JW, Samanta D, Liang H, Semenza GL. 
Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer 
stem cell phenotype. Oncotarget. 2014;5:12509-27. 
8. Chang C, Goel HL, Gao H, Pursell B, Shultz LD, Greiner DL, Ingerpuu S, Patarroyo M, Cao S, Lim E, et 
al. A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bβ1 integrin to sustain 
breast cancer stem cells. Genes Dev. 2015;29:1-6. 
 13 
 
9. Nandy SB, Arumugam A, Subramani R, Pedroza D, Hernandez K, Saltzstein E, Lakshmanaswamy R. 
MicroRNA-125a influences breast cancer stem cells by targeting leukemia inhibitory factor receptor which 
regulates the Hippo signaling pathway. Oncotarget. 2015;6:17366-78. 
10. Vici P, Mottolese M, Pizzuti L, Barba M, Sperati F, Terrenato I, Di Benedetto A, Natoli C, Gamucci T, 
Angelucci D,  et al. The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-
positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. Oncotarget. 2014;5:9619-
25. 
11. Vici P, Ercolani C, Di Benedetto A, Pizzuti L, Di Lauro L, Sperati F, Terrenato I, Gamucci T, Natoli C, 
Di Filippo F, et al. Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast 
cancer treated with neoadjuvant chemotherapy. J Exp Clin Cancer Res. 2016;35:62. 
12. Di Benedetto A, Mottolese M, Sperati F, Ercolani C, Di Lauro L, Pizzuti L, Vici P, Terrenato I, Sperduti 
I, Shaaban AM, et al. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. 
Oncotarget. 2016 May 27. doi: 10.18632/oncotarget.9668. [Epub ahead of print] 
13. Du X, Yu A, Tao W. The non-canonical Hippo/Mst pathway in lymphocyte development and functions. 
Acta Biochim Biophys Sin (Shanghai). 2015;47:60-4.   
14. Pefani DE, O'Neill E. Hippo pathway and protection of genome stability in response to DNA damage. 
FEBS J. 2016;283:1392-403.  
15. Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nat 
Rev Cancer 2016; 16: 35-42 
16. Vici P, Di Benedetto A, Ercolani C, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Terrenato I, Dattilo R, Botti 
C, et al. Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer 
patients treated with neoadjuvant chemotherapy: An exploratory analysis. Oncotarget. 2015;6(40):42773-80. 
 14 
 
17. Díaz-Martín J, López-García MÁ, Romero-Pérez L, Atienza-Amores MR, Pecero ML, Castilla MÁ, 
Biscuola M, Santón A, Palacios J. Nuclear TAZ expression associates with the triple-negative phenotype in 
breast cancer. Endocr Relat Cancer. 2015;22(3):443-54.  
18. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, 
Baehner FL, Penault-Llorca F, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: 
recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259-71.  
19. Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, 
Baselga J, et al. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and 
Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: 
A Secondary Analysis of the NeoALTTO Trial. JAMA Oncol. 2015;1:448-54.  
20. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett 
R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant 
chemotherapy in breast cancer. J Clin Oncol 2010; 28:105-113.  
21. Buglioni S, Vici P, Sergi D, Pizzuti L, Di Lauro L, Antoniani B, Sperati F, Terrenato I, Carosi M, 
Gamucci T, et al. Analysis of the hippo transducers TAZ and YAP in cervical cancer and its 
microenvironment. Oncoimmunology. 2016;5:e1160187. 
22. Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1. 
Cancer Res. 2015;75(11):2139-45.  
23. Hamilton G, Yee KS, Scrace S, O'Neill E. ATM regulates a RASSF1A-dependent DNA damage response. 
Curr Biol. 2009;19:2020-5.  
24. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, Bakalarski CE, Zhao Z, 
Solimini N, Lerenthal Y, et al. ATM and ATR substrate analysis reveals extensive protein networks 
responsive to DNA damage. Science. 2007;316:1160-6. 
 15 
 
25. Pefani DE, Latusek R, Pires I, Grawenda AM, Yee KS, Hamilton G, van der Weyden L, Esashi F, 
Hammond EM, O'Neill E.. RASSF1A-LATS1 signalling stabilizes replication forks by restricting CDK2-
mediated phosphorylation of BRCA2. Nat Cell Biol. 2014;16:962-71. 
26. Aylon Y, Yabuta N, Besserglick H, Buganim Y, Rotter V, Nojima H, Oren M. Silencing of the Lats2 
tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven 
cell transformation. Oncogene. 2009;28:4469-79.  
27. Zhou X, Wang S, Wang Z, Feng X, Liu P, Lv XB, Li F, Yu FX, Sun Y, Yuan H, et al. Estrogen regulates 
Hippo signaling via GPER in breast cancer. J Clin Invest. 2015;125:2123-35.  
28. Lin CH, Pelissier FA, Zhang H, Lakins J, Weaver VM, Park C, LaBarge MA. Microenvironment rigidity 
modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription 
factors. Mol Biol Cell. 2015;26:3946-53.  
29. Gaillard H, García-Muse T, Aguilera A. Replication stress and cancer. Nat Rev Cancer 2015; 15: 276-289 
30. Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic 
instability. Nat Rev Mol Cell Biol. 2011; 12:385-92.  
31. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C8, 
Paepke S, Gerber B, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early 
breast cancer (GeparSixto;GBG 66): A randomised phase 2 trial. Lancet Oncol 2014; 15:747-756,  
32. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo 
G, Port ER, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week 
paclitaxel followed by dosedense doxorubicin and cyclophosphamide on pathologic complete response rates 
in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33:13-21. 
  
 16 
 
Table 1: Baseline characteristics of breast cancer patients included in this study (n = 57) 
 N % 
Age at diagnosis   
Median (IQR) 50 (21) 
Menopausal status   
Yes 30 53 
No 27 47 
Clinical Stage    
II A 17 30 
II B 17 30 
III A 15 26 
III B 6 11 
III C 2 3 
Grade   
G1-G2 11 19 
G3 46 81 
Ki-67 Median   
Low (<35%) 26 46 
High (≥35%) 31 54 
Ki-67   
<14% 2 4 
≥14% 55 96 
Molecular Subtype   
Luminal B 15 26 
HER2-enriched 15 26 
Triple-Negative 27 48 
Stromal TIL   
< 50% 49 86 
≥ 50% 8 14 
pCR (pT0/is - N0)   
Yes 28 49 
No 29 51 
pCR (pT0 – N0)   
Yes 23 40 
No 34 60 
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Table 2: expression pattern of pMST1/2 and pLATS1/2 in HER2-positive and triple-negative breast cancer (n 
= 57) 
 N % 
pLATS1/2 stromal TILs   
Negative 33 58 
Positive, Range (10%-80%) 24 42 
pLATS1/2 nuclear   
Negative  12 21 
Positive, Range (10%-80%) 45 78 
pLATS1/2 cytoplasm    
Negative 49 86 
Positive, Range (50%-80%) 8 14 
pMST1/2 stromal TILs    
Negative 43 75 
Positive, Range (10%-80%) 14 25 
pMST1/2 nuclear   
Negative  32 56 
Positive, Range (10%-80%) 25 44 
pMST1/2 cytoplasm    
Negative 32 56 
Positive, Range (60%-80%) 25 44 
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Table 3: Significant or borderline significant associations between the molecular markers of interest 
(pMST1/2and pLATS1/2)and clinical-pathological factors. 
 pMST1/2cyt  
 Negative  Positive p-value 
Molecular Subtype  
TNBC 20 (74) 12 (40) 0.010° 
Her2-positive 7 (26) 18 (60)  
 pLATS1/2
cyt  
 Negative Positive  
Grade  
G1-G2 7 (14) 4 (50) 0.037°° 
G3 42 (86) 4 (50)  
 pMST1/2nuc  
 Negative  Positive  
 N (%) N (%)  
Molecular Subtype  
TNBC 9 (33) 23 (77) 0.001° 
Her2-positive 18 (67) 7 (23)  
 pMST1/2 stromal TILs  
 Negative  Positive  
 N (%) N (%)  
Age at diagnosis  
(median (years); min-max) 54 (27-77) 43 (35-77) 0.012* 
Menopausal Status    
Pre 16 (37) 11 (79) 0.012°° 
Post 27 (63) 3 (21)  
Molecular Subtype    
TNBC 17 (40) 10 (71) 0.063°° 
Her2-positive 26 (60) 4 (29)  
 pLATS1/2 stromal TILs  
 Negative  Positive  
 N (%) N (%)  
Age at diagnosis  
(median (years); min-max) 55 (27-76) 48 (27-77) 0.047* 
Menopausal Status    
Pre 10 (33) 17 (63) 0.025° 
Post 20 (67) 10 (37)  
Ki-67    
Low 19 (63) 7 (26) 0.005° 
High 11 (37) 20 (74)  
Molecular Subtype    
TNBC 8 (27) 19 (70) 0.001° 
Her2-positive 22 (73) 8 (30)  
*Mann-Whitney test; °Chi2 test; °° Fisher-exact test 
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Table 4: Relationship between pMST1/2 expression and pCR (n = 57). 
 pCR (pT0/is pN0)  
 Yes No p-value 
pMST1/2
nuc
     
Negative   21 (66%) 11 (34%) 0.005 
Positive  7 (28%) 18 (72%)  
pMST1/2
cyt
    
Negative  12 (37%) 20 (63%) 0.047 
Positive  16 (64%) 9 (36%)  
 pCR (pT0 pN0)  
 Yes No p-value 
pMST1/2
nuc
    
Negative  17 (53%) 15 (47%) 0.026 
Positive   6 (24%) 19 (76%)  
pMST1/2
cyt
    
Negative 9 (28%) 23 (72%) 0.033 
Positive  14 (56%) 11 (44%)  
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Figure 1: Representative examples of immunohistochemical expression of pMST1/2 and pLATS1/2 in four 
breast cancer cases (a,b,c,d). Panels a and b show two cases with cytoplasmic pMST1/2 (a) and cytoplasmic 
pLATS1/2 (b) expression with concomitant expression in stromal TILs. Panels c and d show two cases with 
nuclear pMST1/2 (c) and nuclear pLATS1/2 (d) expression with concomitant expression in stromal TILs. 
Slide magnification x 40, inset magnification x 20. Scale bar 30 μm. 
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Figure 2: Bar charts illustrating the association between pMST1/2
cyt
 and TAZ (panel A), and between 
pMST1/2
nuc
 and pChk1 (panel B). 
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Figure 3: Univariate regression models for pCR (pT0/is pN0 and pT0 pN0) illustrating OR and 95%CI: 
clinical-molecular variables are reported including stage (III vs II), grade (G3 vs G1-2), Ki-67 levels (high vs 
low), molecular subtypes (HER2-positive vs triple-negative), pMST1/2
cyt
 (positive vs negative) and 
pMST1/2
nuc
 (positive vs negative). 
